HALO
Halozyme Therapeutics, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders +21.4% ·
aandelenstroom +24.3% ·
netto nieuwe posities +17.6%
· formule
Brede accumulatie: stijgende aandelen bij meer houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2024
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 502.79K | $49.11M | n/a | n/a |
| Q2 2026 | 131 | -1 | 91.15M | $6.60B | +6 | −8 |
| Q1 2026 | 136 | +1 | 88.77M | $5.36B | +7 | −7 |
| Q4 2025 | 135 | -1 | 97.38M | $6.16B | +1 | −1 |
| Q3 2025 | 22 | +1 | 49.86M | $3.66B | +1 | −1 |
| Q2 2025 | 19 | 0 | 43.24M | $2.25B | n/a | n/a |
| Q1 2025 | 16 | -1 | 15.61M | $996.39M | n/a | −1 |
| Q4 2024 | 17 | +3 | 17.59M | $840.95M | +4 | −1 |
| Q3 2024 | 13 | -1 | 6.97M | $398.81M | n/a | −1 |
| Q2 2024 | 14 | n/a | 8.14M | $426.06M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 7.18M | n/a | $343.50M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passief) | 3.06M | +0.1% | $146.53M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 1.26M | Nieuw | $60.37M | 0.1% | New | 1 | SEC ↗ ×3 |
| 4 | Norges Bank ✦ (passief) | 1.26M | +15.2% | $60.05M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.22M | -4.1% | $58.25M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 6 | Arrowstreet Capital ✦ | 992.89K | +141.3% | $47.47M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 831.41K | +171.2% | $39.75M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 8 | Capital World Investors ✦ | 748.23K | Nieuw | $35.77M | 0.0% | New | 1 | SEC ↗ |
| 9 | Fisher Asset Management ✦ | 414.72K | +28.0% | $19.83M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 247.03K | +403.0% | $11.81M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 11 | Millennium Management ✦ | 95.42K | +254.5% | $4.56M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 12 | Point72 Asset Management ✦ | 84.83K | Nieuw | $4.06M | 0.0% | New | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 57.37K | -11.9% | $2.74M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 14 | AQR Capital Management ✦ | 52.96K | +0.8% | $2.53M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 15 | Gotham Asset Management ✦ | 47.44K | +9.7% | $2.27M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 26.11K | -89.8% | $1.25M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 17 | Marshall Wace ✦ | 4.43K | Nieuw | $211,607 | 0.0% | New | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Citadel Advisors | $60.37M | 0.1% |
| Capital World Investors | $35.77M | 0.0% |
| Point72 Asset Management | $4.06M | 0.0% |
| Marshall Wace | $211,607 | 0.0% |
Verlaten
| Bridgewater Associates | $659,119 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 630 houders, 119.44M aandelen, $7.40B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 200 aand · $22,102
Officer, Director · 11.90K aand · $1.31M
Officer, Director · 3.09K aand · $336,526
Officer, Director · 4.81K aand · $520,341
Officer, Director · 8.60K aand · $954,867
Officer, Director · 200 aand · $22,739
Officer, Director · 900 aand · $101,502
Officer, Director · 10.30K aand · $1.15M
Officer, Director · 1.78K aand · $197,245
Officer, Director · 9.92K aand · $1.09M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie